Company: HCWB
Filing Date: 2025-02-21
Form Type: DEF 14A
Source: 0001193125-25-032115
Chunk: 97

Company: HCW Biologics Inc.
Filing Date: 2025-02-21
Form: DEF 14A
Chunk 97
---
 be deemed to be the language chosen by the
parties to express their mutual intent and no rules of strict construction will be applied against any party.

m. This Agreement is
intended for the benefit of the parties hereto and their respective successors and permitted assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

- A-43 -

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed as of the Execution Date.

| THE COMPANY:                                |     |                  |
| HCW BIOLOGICS INC.                          |     |                  |
| By:                                         |     | /s/ Hing C. Wong |
| Name: Hing C. Wong                          |     |                  |
| Title:  Founder and Chief Executive Officer |     |                  |

| BUYER:                                          |     |                          |
| SQUARE GATE CAPITAL MASTER FUND, LLC – SERIES 4 |     |                          |
| By:                                             |     | /s/ Christopher Perugini |
| Name: Christopher Perugini                      |     |                          |
| Title:  Managing Partner                        |     |                          |

EXHIBIT A TO REGISTRATION RIGHTS AGREEMENT FORM OF NOTICE OF EFFECTIVENESS OF REGISTRATION STATEMENT [] [], 2025 Equiniti Trust Company, LLC 48 Wall St Floor 23 New York, NY 10005 Re: EFFECTIVENESS OF REGISTRATION STATEMENT Ladies and Gentlemen: We are counsel to HCW Biologics Inc., a corporation incorporated in the State of Delaware (the “ Company”), and have represented the Company in connection with that certain Equity Purchase Agreement, dated as of February 20, 2025 (the “ Purchase Agreement”), entered into by and between the Company and Square Gate Capital Master Fund, LLC—Series 4 (the “ Buyer”) pursuant to which the Company has agreed to issue to the Buyer shares of common stock of the Company, par value $0.0001 per share (the “ Common Stock”), in an amount up to Twenty Million Dollars ($20,000,000.00), which amount may be increased pursuant to the terms and conditions set forth in the Purchase Agreement (the “ Put Shares”), in accordance with the terms of the Purchase Agreement. In connection with the transactions contemplated by the Purchase Agreement, the Company has registered with the U.S. Securities & Exchange Commission the following shares of Common Stock: (1)Put Shares to be